Liquidia Corporation (LQDA)
NASDAQ: LQDAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
LQDA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $4.90B
- Forward P/E
- 15.12
- EPS (TTM)
- -$1.05
- Dividend yield
- None
- 52-week range
- 22.31 – 93.61
- Day range
- 53.98 – 57.21
- Volume / Avg
- 1.69M / 3.52M
- Beta
- —
- Shares outstanding
- 90.11M
52-week range
LQDA stock today
Shares of Liquidia (LQDA) finished lower on Nov 20 at $54.43, a drop of 3.88% or $2.20 per share, versus the S&P 500's 3.70% decline. Trading was light, with 1.69M shares changing hands, about 48% of the average daily volume. At this level, LQDA sits in the middle of its 52-week range of $22.31 to $93.61: 41.9% below the high, set on Aug 11, 2026 and 144.0% above the low.
LQDA is up 57.8% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 87.0%. Liquidia has posted a net loss over the last twelve months (EPS of -$1.05), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Liquidia
Company profileLiquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil which is in phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Roger A. Jeffs Ph.D.
- Headquarters
- Morrisville, NC
- Employees
- 216
- IPO year
- 2018
- Website
- liquidia.com
Financial highlights
Full financialsIn fiscal 2025, Liquidia generated $158.3 million in revenue, up 1031.2% from fiscal 2024. Liquidia reported a net loss of $68.9 million, compared with a loss of $128.3 million a year earlier. Operating margin was -32.5%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $158.32M | $14.00M | $17.49M | $15.94M | $12.85M |
| Growth | +1031.18% | -19.97% | +9.75% | +23.98% | +1637.77% |
| Net income | $-68.92M | $-128.29M | $-78.50M | $-41.02M | $-34.58M |
| EPS (diluted) | $-0.80 | $-1.63 | $-1.21 | $-0.67 | $-0.70 |
Analyst forecast
ForecastConsensus (8 analysts)
buy
Avg. price target
$66.13+21.50%
- Strong buy 1
- Buy 5
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 10, 2026
- EPS actual vs est.
- $-0.04 vs $0.77
- Surprise
- -105.19%
LQDA news
All LQDA news- Liquidia Corporation Appoints Russell Schundler as Chief Strategy Officer and General Counsel Effective November 16, 2026Nasdaq
- LQDA Q3 Earnings Beat Estimates on Robust Yutrepia SalesNasdaqLQDA, UTHR, COLL, AMRX
- Liquidia extends gains as Raymond James upgrades on Yutrepia launchSeeking Alpha
- Liquidia rises 7% after third-quarter results, litigation resolvedSeeking Alpha
- Liquidia (LQDA) Q3 2026 Earnings Call TranscriptNasdaq
- Liquidia plans PH-ILD enrollment completion in 2028 with L606 NDA submission target in 2029Seeking Alpha
- Why is Liquidia stock gaining today?Investing.com
- Liquidia Corporation to Present at 2026 Jefferies Global Healthcare ConferenceGlobeNewswire
Liquidia peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ERASErasca Inc. | 13.61 | -4.29% | $4.78B | vs LQDA |
| MANEVeradermics Incorporated | 119.52 | -3.92% | $5.04B | vs LQDA |
| DNTHDianthus Therapeutics Inc. | 84.55 | -0.33% | $4.76B | vs LQDA |
| PTCTPTC Therapeutics Inc. | 56.42 | -3.27% | $4.71B | vs LQDA |
| COGTCogent Biosciences Inc. | 26.72 | -3.69% | $4.65B | vs LQDA |
| BLTEBelite Bio Inc ADR | 127.38 | -15.65% | $5.17B | vs LQDA |
| TVTXTravere Therapeutics Inc. | 47.00 | -2.69% | $4.51B | vs LQDA |
| IONSIonis Pharmaceuticals Inc. | 26.58 | -2.35% | $4.43B | vs LQDA |
Indexes, lists and sector
Liquidia stock FAQ
What is Liquidia's stock price today?
LQDA last traded at $54.43 as of Nov 20, 4:00 PM EST, down 3.88% on the day. Prices are delayed at least 15 minutes.
Who is Liquidia's CEO?
Dr. Roger A. Jeffs Ph.D. is the chief executive officer of Liquidia Corporation, which has about 216 employees.
What is the LQDA 52-week high?
The 52-week high for LQDA is $93.61 and the 52-week low is $22.31. The stock is currently 41.9% below its high.